http://www.inc.com/glen-blickenstaff/4-critical-traits-of-an-entrepreneur.html
Payments to Doctors by Pharmaceutical Companies Raise Issues of Conflictshttp://www.nytimes.com/2011/11/25/us/payments-to-doctors-by-pharmaceutical-companies-raise-issues-of-conflicts.html?_r=3 Few Contact Lens Users Follow All Care Guidelines, Study Finds New strategies needed to improve compliancehttp://health.msn.com/health-topics/vision/few-contact-lens-users-follow-all-care-guidelines-study-finds Malaria Drug Studied for Treatment of Metastatic Breast Cancer.http://www.fiercebiotech.com/press-releases/malaria-drug-studied-treatment-metastatic-breast-cancer FDA's Efforts to Advance the Artificial Pancreas System and the Challenges Aheadhttp://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/HomeHealthandConsumer/ConsumerProducts/ArtificialPancreas/default.htm Giving thanks can make you happierhttp://www.health.harvard.edu/healthbeat/giving-thanks-can-make-you-happier Visit JANIX at the AAO ConferenceJANIX will be exhibiting at AAO in Orlando Florida from 22 OCT to 25OCT 2011. Stop by the JANIX booth to say "hello". The JANIX Booth will be located at position 265. FDA readies release of long-awaited rules on biosimilars
Monday 26 Sep 2011
by admin |
No Comments
Filed under: General News, Regulations Tags: biosimilars, FDA, JANIX Despite increasingly loud groans from the payer community in healthcare, the FDA has demonstrated repeatedly that it plans to take its time to craft a regulatory pathway for biosimilars. Its current schedule calls for a set of rules by the end of the year. But the long wait may be drawing to an end, with a top regulator signaling that the final regulations may arrive in a matter of days or weeks. Read the rest of the article by John Carroll by clicking here: Report: FDA readies release of long-awaited rules on biosimilars - FierceBiotech http://www.fiercebiotech.com/story/report-fda-readies-release-long-awaited-rules-biosimilars/2011-09-26#ixzz1Z5FgAlS2 Designing a Smarter Patient
Sunday 25 Sep 2011
by admin |
No Comments
Filed under: General News, Patient Recruitment Tags: Clinical Trials, JANIX, Patient Recruitment, Statins By JEROME GROOPMAN and PAMELA HARTZBAND,"I'm comfortable with that," or "No, it wouldn't be comfortable for me." That's what our patients often tell us when faced with a choice about taking a medication or undergoing a procedure. And the discussion usually stops there. But what makes someone comfortable or uncomfortable with one treatment or another, or with no treatment at all? Where do these views come from? And how can patients make better decisions? For answers, we spent four years interviewing scores of patients of different ages. We found that a host of powerful and often hidden influences, inside and outside the patient's mind, can sway thinking and distort judgment. We also discovered that, by unmasking those influences, it is possible for patients to gain greater confidence and control over their medical decisions. Consider the case of Susan Powell (not her real name), a nurse's assistant now in her 50s. She had been healthy all her life, but when she turned 45, she decided to see a primary-care doctor. Susan ate healthy foods and was physically active, but she was a bit overweight, and her blood tests showed that she had high cholesterol. Her doctor prescribed a statin drug and asked her to come back in a month. Statins are among the most commonly prescribed medications in the world. In the U.S. alone, more than 25 million people take the drugs to lower their cholesterol, which is a key factor leading to heart attack and stroke. Soon after seeing her doctor, Susan spoke with an acquaintance at church who had developed muscle pain after starting to take a statin. Susan also thought of her father, who had high cholesterol and never took any medication for it. "People take too many pills," he often told his children. He lived a long, full and active life. Susan decided not to take the statin. Many people decline treatment because they know someone who suffered from side effects or someone who lived well into old age without treatment. Stories deeply affect all of us, and they can make real the risks and benefits that might otherwise seem abstract—but they can also distort our vision by making the rare appear routine. Statistics can help to put lessons drawn from stories into a larger context, letting us make a more considered choice than we possibly could by using narratives alone. At Susan's follow-up appointment a month later, her doctor told her that "by taking a statin pill, you'll reduce your risk of a heart attack over the next 10 years by as much as 30%." The risk of side effects, she continued, was very small, and the benefits far outweighed the risk. Susan promised to give it serious thought. She continued to search for information, reading everything she could about cholesterol. What caught her eye was a government-sponsored link to a "10-Year Heart Attack Risk Calculator." She entered her age, total cholesterol number of 240, and "good" cholesterol (HDL) of 37. She was not a smoker, her blood pressure was fine, and she was on no medications. The result: "Risk Score: 1%: Means 1 of 100 people with this level of risk will have a heart attack in the next 10 years." This means that 99 of 100 people like me won't have a heart attack in the next 10 years, Susan told herself. She started to feel much better. She had found a key number in health literacy: her risk for disease without treatment. Without treatment, Susan's risk for a heart attack was 1 in 100. If 1 in 100 women has a heart attack, that means 2 in 200 do, or 3 in 300. The statin treatment reduces risk by 30%, or about one-third. Let's apply that benefit to a group of 300 women like Susan, where three would have a heart attack without taking statins. If we treat them all, we would prevent one heart attack—because we protect one-third of those three. The other two women would still have a heart attack despite taking the medicine. The remaining 297 would not have had a heart attack even without the medication, so they wouldn't benefit from taking it. This statistic comes as a surprise to many people. When you hear that a statin lowers Susan's risk by 30%, it sounds as if she is at a 100% risk of suffering a heart attack if she doesn't take the medication. Another component of health literacy is understanding the risks of a therapy. Statins cause muscle pain in 1% to 10% of people who take them. However, if we "flip" the frame, the number without any side effects is 90 to 99 out of 100, a much more reassuring statistic. Advertisements for drugs may include statistics, but fundamentally these ads are designed to communicate a compelling tale. Over the weeks that followed her appointment with her physician, Susan paid particular attention to ads for statins. Once she started looking for them, they seemed to be everywhere. In 2007, a team of researchers from the UCLA Medical Center and other medical centers studied prescription drug ads broadcast on national networks. They found that the average American TV viewer sees over 1,000 prescription drug ads in the space of a year. That's 16 hours all told—much more time than the average person spends with his or her primary-care physician. The study concluded that the large majority of TV ads fail to fulfill an educational purpose. But they clearly work, at least from the point of view of sales: Every $1,000 spent on advertising translated into 24 new prescriptions, according to an analysis by the House Energy and Commerce Committee. Another illuminating study, conducted by researchers at the Dartmouth Institute for Health Policy and Clinical Practice, examined the impact of printed drug ads on patient preferences. One group was given actual ads. A second group received the same ads, except that the brief summary at the end of the text was replaced by a "drug-facts box." The box presented information in a clear, accessible fashion, similar to the way we recalculated the benefits and risks of a statin for Susan. The results of the Dartmouth research are impressive. Nearly two-thirds of the group that saw the original ads overestimated the benefits of the treatment. They believed it was 10 times more effective than it actually was. But nearly three-quarters of the participants who saw the information in the drug-facts box correctly assessed the actual benefits of the treatment. Even more striking was another finding. When people were given readily understandable information about the statin's actual benefit in preventing future heart disease, nearly twice as many said they wouldn't take the drug in light of its side effects. When given clearer information, the patients weighed the risks and benefits differently from their doctors and were less likely to take the medication. Susan Powell's decision was not simple. More than five years later, her doctor continues to encourage her to take the drug, and she continues to say no—but now, at least, she can more fully explain why. —Dr. Groopman and Dr. Hartzband are on the faculty of Harvard Medical School and the staff of Beth Israel Deaconess Medical Center, both in Boston. This essay is adapted from their new book, "Your Medical Mind: How To Decide What Is Right for You." Article Reference: http://online.wsj.com/article/SB10001424053111903791504576584732337016232.html?mod=wsj_share_in_bot Speed-of-light results under scrutiny at Cern
Friday 23 Sep 2011
by admin |
No Comments
Filed under: General News Tags: Cern, JANIX, Sped of Light By Jason Palmer Science and technology reporter, BBC News: "A meeting at Cern, the world's largest physics lab, has addressed results that suggest subatomic particles have gone faster than the speed of light. The team presented its work so other scientists can determine if the approach contains any mistakes. If it does not, one of the pillars of modern science will come tumbling down. Antonio Ereditato added "words of caution" to his Cern presentation because of the "potentially great impact on physics" of the result." Read the rest of the article at this link: http://www.bbc.co.uk/news/science-environment-15017484
Physician Recruitment |
Employment | Copyright © 2011 Janix | Site Design by Nuvoyc Media 27101 Aliso Creek Road, STE 100, Aliso Viejo CA 92656, USA | Email: bd@janix.com | Phone: +1.949.251.9800 | Fax: +1.619.489.3660 |







